Indian pharma companies Aurobindo Pharma, Glenmark and Zydus have withdrawn their products from the market due to manufacturing defects in the US market. According to the latest enforcement report of the US Food and Drug Administration (USFDA), this step has been taken due to manufacturing related irregularities in these medicines.
Aurobindo Pharma's move
Aurobindo Pharma USA Inc, a subsidiary of Hyderabad-based Aurobindo Pharma, has recalled more than one lakh bottles of cinacalcet tablets. These tablets are used in the treatment of hyperparathyroidism. USFDA said that the amount of N-nitroso cinacalcet impurity in these tablets was found to be more than the limit recommended by the FDA. The company started the process of recalling these products under the Class-2 category on november 7 this year.
Glenmark's recall
Glenmark Pharma's US subsidiary has recalled about 90,000 bottles of Diltiazem Hydrochloride capsules. These drugs are used to treat high blood pressure and heart problems. This recall has also happened due to manufacturing defects.
Zydus statement
Zydus Pharmaceuticals (USA) Inc has recalled 4,404 cans of Esomeprazole magnesium due to labeling errors. This drug is used to treat stomach and esophagus problems, such as gastroesophageal reflux disease (GERD). The company started the process of recalling the affected products from the market on november 14.
Effect on the stock market
The impact of these incidents was seen on the shares of the companies in Friday's trading session. Aurobindo Pharma's stock closed down 0.59% or 7.20 points at Rs 1207.95. Glenmark Pharma shares closed at Rs 1517.20, down 1.13% or 17.30 points. Zydus Lifescience shares closed at Rs 978.35, up 0.28% or 2.70 points.
click and follow Indiaherald WhatsApp channel